This study compares EG-1962 to enteral nimodipine in the treatment of aneurysmal subarachnoid hemorrhage.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
374
Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
Proportion of subjects with a favorable outcome measured on the Extended Glasgow Outcome Scale [Primary Efficacy Endpoint]
Proportion of subjects with a favorable outcome measured on the Extended Glasgow Outcome Scale (GOSE) at Day 90
Time frame: 90 Days
Proportion of subjects with favorable neurocognitive outcome measured by the Montreal Cognitive Assessment [Secondary Efficacy Endpoint]
Proportion of subjects with favorable neurocognitive outcome measured by the Montreal Cognitive Assessment (MoCA) at Day 90
Time frame: 90 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham Hospital
Birmingham, Alabama, United States
Dignity Health; St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
University of California, San Francisco-Fresno
Fresno, California, United States
Keck Hospital of USC
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
UCSF
San Francisco, California, United States
Yale New Haven Hospital (YNHH)
New Haven, Connecticut, United States
UF Health Shands Florida
Gainesville, Florida, United States
Baptist Medical Center/Lyerly Neurosurgery
Jacksonville, Florida, United States
...and 69 more locations